Australia's medicines and medical devices regulator on Monday formally recognised India's Covaxin, a vaccine against the coronavirus as the country's border was reopened for the first time in nearly 20 months.
In a virtual conference from Moscow, Dmitriev said Sputnik V is not only 'one of the most effective' but also among the 'affordable' vaccines in the world.
In a joint statement posted on their respective twitter accounts, the companies said Serum Institute Chief Executive Officer Adar Poonawalla and Bharat Biotech Chairman Krishna Ella communicated their combined intent to develop, manufacture and supply the COVID-19 vaccines.
However, the "good news" is that the US vaccines are effective against the Delta variant, said Fauci, the head of the National Institutes of Allergy and Infectious Diseases.
'Whenever you roll out: effectiveness is important, operational logistics are important, side effects are important and vaccine hesitancy is important.'
Poonawalla said the price will be around USD 5-6 per dose with an MRP of around Rs 1,000 for the two necessary doses.
Companies which have been dropped from the list include Tata Motors, Hindustan Unilever, MRF, Glaxo SmithKline Consumer Healthcare, Pfizer, Dr Reddy's Labs, Glenmark Pharmaceuticals, HDFC and Kotak Mahindra Bank
Like the UK variant identified earlier, the new variant of the novel coronavirus is also driving a massive resurgence of the disease in South Africa, with experts warning the country is probably facing a much larger second wave.
Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.
In a report submitted Monday to Rajya Sabha chairman and Vice President M Venkaiah Naidu, the Parliamentary Standing Committee on Home Affairs also said there was a need for a comprehensive public health law to keep a tab on private hospitals and check black-marketing of medicines.
The international team of researchers combined lab-based experiments and epidemiology of vaccine breakthrough infections, showing that the Delta variant is better at replicating and spreading than other commonly-observed variants.
Communications between the USTR and the world's most powerful pharmaceutical and trade lobbying groups reveal that many raised concerns about India's push to exempt Covid vaccines from intellectual property.
The Department of Health and Social Care said a total of 81,959,398 doses of COVID vaccines have been administered in the UK, with 46,227,101 people receiving a first dose (87.8 per cent) and 35,732,297 people receiving both doses (67.8 per cent).
"The concrete actions are a stern indication that Government of India is making all out efforts to increase vaccine production in the country as well as attracting foreign vaccine manufacturers to supply the required vaccine doses for national Covid vaccination programme," the ministry in a statement.
According to the sources, there are limited prospects of J&J exporting its vaccine from the US to other countries in the near future and the "entire production" at the BE facilities in India, beginning July/August, will be handed over to the pharma giant under a contract between the companies.
The Johnson and Johnson and Sputnik vaccines should be approved now, as should the Pfizer and Moderna ones, suggests Naushad Forbes. Leave it to the companies to figure out how to put in place the right chilling infrastructure. Don't let a lack of approvals deprive the country of availability, suggests Naushad Forbes.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
Health Minister Harsh Vardhan said the COVID-19 vaccine will be available in the next few months and it is estimated that by July-August 400-500 million doses will be made available for 25-30 crore people.
The primary objective was to get the adult vaccine as children rarely have a severe form of the disease. Once schools reopen, the demand for vaccines for children under 12 may soar.
In a development that might result in India's leading drug maker Ranbaxy selling a generic version of Pfizer's blockbuster drug Lipitor sooner than expected in the US market, the United States patent office has made an initial rejection of Pfizer's claim on the basic patent on Lipitor.
To enable large-scale vaccine studies to take place across the UK, the aim is to get 500,000 people signed up by October, which is considered vital in the fight against coronavirus.
In a boost to Ranbaxy in its ongoing litigation over anti-cholesterol drug Lipitor (atorvastatin) against Pfizer, a Norway court today ruled that four of the US pharma giant's patents were either invalid or not infringed by the Indian company.
The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
Asserting that India is on track to vaccinate its entire adult population by December, top officials on Monday said a blueprint is in place to ensure a total supply of 187.2 crore doses by the year-end that would be enough for the country's 94 crore 18-plus population.
The Biden administration had been under pressure to send the excess COVID-19 vaccines with the US to nations like India, which are facing severe vaccine shortages.
'You will not have a vaccine for everyone initially.'
There is a process to be followed for EUL and pre-qualification of vaccines under which a company has to complete phase 3 trials and submit the whole data to the regulatory department of WHO which is examined by an expert advisory group," Swaminathan said.
Will syringe shortage puncture India's Covid vaccine plans?
The women who made India proud in Tokyo are set to be the Independence Day mascots. Invite from the PM has already gone out to these achievers to be guests of honour on August 15.
Vaccines Covishield and Covaxin work against SARS-CoV-2 variants Alpha, Beta, Gamma and Delta, while effectiveness tests against the Delta Plus variant is ongoing, the government said.
Country's biggest drug maker, Ranbaxy Laboratories Ltd on Wednesday said a US Appeals Court has ruled in its favour in the patent infringement case with Pfizer for cholesterol-lowering drug Atorvastatin (Lipitor).
Giuliani, 76, has been taken to the Medstar Georgetown University Hospital in Washington DC, according to US media reports.
A technical advisory group of the UN health agency which met on Tuesday has sought "additional clarifications" from Bharat Biotech for Covaxin to conduct a final "risk-benefit assessment" for Emergency Use Listing of the vaccine.
It is in no way a government of the economic Right. The Right is limited to religion and nationalism. The rest is as Left as the Congress or any other party, observes Shekhar Gupta.
As many as 721,469 appointments were made through the national booking service on Friday -- the day of the announcement -- at an average of more than eight every second. To cope with demand, the NHS said it is using stadiums and football grounds as giant vaccination centres.
The Serum Institute of India, Bharat Biotech and Pfizer have applied to the DCGI seeking emergency use authorisation for their COVID-19 vaccine candidates and are awaiting approval.
The Serum Institute of India has stockpiled 40 mn-50 mn doses and is adding more every week. Most of these will come to India.
An important focus of the dry run will be on management of any possible adverse events following immunisation.
A US court has ruled against Ranbaxy in its case for non-infringement and invalidation of two patents of its competitor Pfizer
Close on the heels of the UK high court delivering a mixed verdict on the patent case of cholesterol lowering drug, atorvastastin between Ranbaxy and Pfizer, a Norwegian court has given another mixed ruling.\n\n
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances